COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 2 FDA records to the applicant name Sun Pharmaceutical Industries, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 3, 1999 to Nov 2, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MVF appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P990019, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 29 Dunham Rd., Billerica, MA, 01821. Recorded on P990019/S010, decision dated Nov 2, 2026.
Device categories in this collection
System, Laser, Photodynamic Therapy.
Changes described in PMA records
The FDA recorded an approval decision on 2026-11-02 for P990019/S010, a supplement to the BLU-U® Blue Light Photodynamic Therapy Illuminator (Model 4170E) held by Sun Pharmaceutical Industries, Inc. The device falls under the photodynamic therapy laser system category, with product code MVF and a listed specialty of general and plastic surgery.
The supplement is recorded as a real-time process submission with the stated reason of change to design, components, specifications or material. Its recorded scope is software changes adding error remediation approaches and optimization of software intercommunications. This decision covers that supplement only, not a new approval of the underlying system. The source lists no supporting documents, so the specific software versions, affected components and review basis remain unknown.
FDA approval-order wording
approval for software changes adding error remediation approaches and optimization of software intercommunications.
Nov 2, 2026 · Real-Time ProcessFDA’s recorded scope: The devices is indicated for use in Photodynamic Therapy with Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp.
Dec 3, 1999Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.